Angiogenesis and Cancer Drug Discovery Group, Basic and Translational Cancer Research Centre, European University Cyprus, Nicosia, Cyprus.
Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus.
Front Endocrinol (Lausanne). 2023 Jul 3;14:1217730. doi: 10.3389/fendo.2023.1217730. eCollection 2023.
Characterized by a complex pathophysiology that includes the intraneuronal formation of neurofibrillary tangles and the extracellular deposition of β-amyloid plaques, Alzheimer's disease (AD) is a terminal neurodegenerative disease that causes dementia in older adults. Oxidative stress in the brain is considered as one of the contributing factors to the pathogenesis of AD, and thus, antioxidants have attracted much interest as potential therapeutic agents against the disorder. Natural antioxidants are typically characterized by low acute and chronic toxicity, which facilitates their potential therapeutic application. One important molecular target for the beneficial effects of natural antioxidants is the nuclear factor erythroid-derived 2-related factor 2 (NFE2L2/NRF2). NRF2 is a key transcription factor that orchestrates the cellular antioxidant response through regulating the expression of oxidative stress-related genes harboring the antioxidant response element (ARE) in their promoters. Indeed, in the case of excessive oxidative damage, NRF2 migrates to the nucleus and binds to ARE, activating the transcription of antioxidant protector genes. There is increasing evidence that NRF2 is implicated in AD pathology through dysfunction and altered localization, which renders it as a potential therapeutic target for AD. Thus, this review summarizes the most recent (2018-2023) advances on the NRF2-modulating activity of natural antioxidants observed and in AD animal models. This information will help elucidate the molecular mechanisms governing the antioxidant activity of such phytochemicals to highlight their therapeutic potential against common neurodegenerative diseases, such as AD.
阿尔茨海默病(AD)是一种终末神经退行性疾病,会导致老年人痴呆,其特征是复杂的病理生理学,包括神经元内神经原纤维缠结的形成和β-淀粉样斑块的细胞外沉积。大脑中的氧化应激被认为是 AD 发病机制的一个促成因素,因此,抗氧化剂作为治疗该疾病的潜在治疗剂引起了广泛关注。天然抗氧化剂的特点通常是急性和慢性毒性低,这有利于它们的潜在治疗应用。天然抗氧化剂的有益作用的一个重要分子靶标是红细胞衍生 2 相关因子 2(NFE2L2/NRF2)。NRF2 是一种关键的转录因子,通过调节其启动子中含有抗氧化反应元件(ARE)的氧化应激相关基因的表达,协调细胞抗氧化反应。事实上,在氧化损伤过度的情况下,NRF2 迁移到细胞核并与 ARE 结合,激活抗氧化保护基因的转录。越来越多的证据表明,NRF2 通过功能障碍和位置改变与 AD 病理学有关,使其成为 AD 的潜在治疗靶点。因此,本综述总结了最近(2018-2023 年)关于天然抗氧化剂对 NRF2 调节活性的研究进展,并在 AD 动物模型中观察到了这些进展。这些信息将有助于阐明这些植物化学物质的抗氧化活性的分子机制,突出它们在治疗常见神经退行性疾病(如 AD)方面的治疗潜力。